European Organisation For Research And Treatment Of Cancer - Eortc

This phase 3 trial compares enzalutamide alone versus enzalutamide plus radium-223 (Ra223) in 446 men with castration-resistant prostate cancer that has spread to bones but causes few or no symptoms. The goal is to see if the combination delays cancer progression on scans. Partic…

This study compares a new oral drug, darolutamide, to standard hormone therapy (ADT) in men with prostate cancer that still responds to hormones. About 250 men will be randomly assigned to receive either the pill or injections. The main goal is to see if the pill can lower PSA le…

This study tests the drug nivolumab in 55 people with advanced thymoma or thymic carcinoma that has worsened after initial chemotherapy. The goal is to see if nivolumab can slow cancer growth and how safe it is. Participants receive nivolumab infusions, and researchers track tumo…

This study looks at whether a targeted drug called palbociclib, taken as a pill for two years alongside standard hormone therapy, can replace chemotherapy for older adults (age 70+) with high-risk, hormone-receptor-positive, HER2-negative early breast cancer. The goal is to see i…

This phase 2 trial studies the best strategy for giving the drug osimertinib to people with advanced EGFR-mutant non-small cell lung cancer. It compares starting osimertinib right away versus using it after another drug stops working. The study also checks if blood tests (liquid …

This study gathers medical records and tumor samples from 200 men with breast cancer to learn more about the disease. It has two parts: looking back at past cases (1990-2010) and following new cases for 30 months. The goal is to understand how the disease behaves and how it is tr…

This study looks at how gynecological cancer survivors feel and function after finishing their main treatment. About 1,100 women who are currently cancer-free will fill out questionnaires about their quality of life, anxiety, and sexual health. The goal is to learn what matters m…